Dr Reddy’s Eyes Double-Digit FY26 Growth

dy’s Laboratories is forecasting robust double-digit growth for FY26, driven by the launch of semaglutide and advancements in its product pipeline, according to CEO Erez Israeli. The company is also focusing on resuming manufacturing operations across the US to bolster its market presence. This optimistic outlook underscores y’s strategic efforts to capitalize on high-demand therapeutics and expand its global footprint.